Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model

Temozolomide (TM) has anti-tumor activity in patients with malignant glioma. Implantable poly (d,l-lactide-co-glycolide) (PLGA) microparticles of TM (TM–MS) have been developed, enhancing the cytotoxicity of TM to Glioma C6 cells [1]. Vatalanib, as anti-angiogenic agent, has also shown anti-tumor activity with malignant gliomas [1] and [2]. We examined the combined effects of TM–MS and vatalanib in a rat orthotopic glioma model and found TM–MS offered a greater tumor inhibition than TM, and combination treatment with both of them improved the survival time versus single agent therapy. The combination treatment also demonstrated an inhibition to rat glioma tumors, a significant decrease in cell proliferation, an increase in apoptosis, and a lower microvessel density within the glioma tumors. The results suggest that TM–MS can more effectively inhibit tumor than TM, and combination treatment with TM–MS and vatalanib inhibits tumor growth and angiogenesis and may prove to be a promising therapy for malignant gliomas.

Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis, increases tumor cell apoptosis in an orthotopic glioma model. The combined chemotherapy may prove to be a promising therapy for malignant gliomas.Figure optionsDownload as PowerPoint slide